Tainted Valsartan Alleged For Kidney Cancer Diagnosis

Tainted Valsartan Alleged For Kidney Cancer Diagnosis

Introduction

According to the latest lawsuit filed in the Superior Court of New Jersey on June 5, a woman from Tennessee has alleged Solco Healthcare, Prinston Pharmaceutical, Inc., and Huahai US, Inc. for her kidney cancer caused due to the intake of the recalled valsartan pills.

The plaintiff claims she underwent diagnosis and treatment of kidney cancer, which included the surgical removal of a tumor and a partial nephrectomy following the exposure to the pills that were recalled in recent months due to the presence of cancer-causing chemicals N-nitrosodimethylamine (NDMA) or N-Nitrosodiethylamine (NDEA). The defendants further face allegations of a manufacturing defect, strict liability, negligence, failure to warn, and loss of consortium. The plaintiff and her husband both have claimed compensatory and punitive damages.

The case joins a growing number of lawsuits pending in District Courts across the U.S. against Valsartan. Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.